With this novel approach, therapeutic iNSCs embedded in the CS hydrogel can be delivered once at the time of surgery, migrate to invasive tumor foci, and constitutively secrete TRAIL or other cytotoxic agents to completely eradicate GBM. This evidence concerns the gene TNFSF10 and glioblastoma.